Here are a few items, not enough room in one post.
o MicroRNAs are acknowledged as outstanding biomarkers: Master gene
regulators, highly tissue specific, in most major diseases and extremely
o Rosetta has access to over half of known microRNAs: (29 patents issued,
41 patent applications; cover ~1/3 of public microRNAs, access to ~3/4)
o Track record for consistently bringing to market microRNA diagnostics: 6
tests launched to date
o Next big thing: Blood-based assays using microRNAs, focused on large
unmet needs in early detection of disease in several different disease areas
o Mid-term: Predictive biomarker collaborations with Big Pharma and Med
Tech companies (enabling personalized medicine)
o Test identifies tumor origin in Cancer of Unknown and Uncertain Primary
(CUP); identifies 42 tumor origins using microarray platform
o Important for treatment decisions; allows for more targeted treatment
o High level of accuracy: Overall specificity up to 99%; sensitivity for a
single answer prediction of 90%, overall sensitivity of 85%
• Four studies by M. D. Anderson, Heidelberg University and Greek collaborators
showed 80-92% concordance in actual CUP patients
• More accurate than published data from competitors
o microRNA approach provides competitive advantage
• High tissue specificity leads to higher level of accuracy
• Stability of sample leads to lower failure rates
o $600M market opportunity in the US
• 200,000 CUP patients per year in US
• Medicare claims being paid at a rate of $3,570/test (July 2012)
• Co-marketing arrangement with Precision Tx, a leading oncology diagnostic
company; launched October 2012
Most other companies have a share price increase on the promise of sales. ROSG has absolutely no credibility with investors.
The truth is they just got medicare approval last year and only hired precision last October. We can't go off of 2012 sales. This stuff takes a little time. Sales will pick up in time. Realistically, sales just started in November has the emphasis on selling just began.
Well I have a love hate relationship here....love the product, hate the company. I would love to see this thing get sold to J&J or someone else who could do the RNA products some justice.
Lol Angelina is "compelling news"? Your not seriously trying to convince people to buy with that are you? You obviously bought some of this yesterday or the day before. Best advice is to cut your losses here before this slips back down to the 3.20's. I dont care either way, Im not short or long. Just trying to save a few innocent souls from this pumpscam.
lol, fake people with what? Only thing I suggest is people do their own homework and be careful here. Anyone who does the proper DD will see their burn rate and how much cash they really have left. They will be out of money in a year and a half. That means sell the company or dilute more.
You are the one who obviously has an agenda here to pump this. Maybe you bought some at $4, i dont know and dont care.
We got the compelling news with Angelina and genetic testing. We got medicare reimbursement for another product already submitted for approval. Precision is selling the product (conference call said March best month ever) ASCO coming up, buyout possibilities. It's all good.
Jon Kelly at least you know he was short. These other guys like Barganbuy and Edgar try to fake you out like they aren't. These guys downplay every run. Paid Bashers.
OK. So tell investors investors something good about this company. They have approved products and virtually no sales. They have partnerships that aren't working. They burn cash without anything to show for it. Please, tell us something good. Anything at all.
Wrong, there is no money in this being short. You must have just wandered into this stock and dont know the history here. I think the product is revolutionary, and it should be selling like hotcakes. I think...scratch that...I KNOW the leadership is horrible and that they have stabbed retail investors in the back with dilutions and poor investor relations.
Go ahead and dont believe me, dont believe their financial statements and burn rate either. Do yourself a favor and do your homework on this. They had 2 years of cash left EOY 2012, and now have burned through 1/4 of that.
All I know is you are short sellers who have nothing good to say about the stock and the products in the pipeline, so we must discount every thing you have to say.
Author leaves out the burn rates of each company. ROSG has only 1.5 years of cash left, and it will continue to burn it. I am sure the author was comparing the cash on hand that was reported for the EOY 2012, as thats the last thing put out there by ROSG.
If there were any significant sales milestones (i.e. first 1,000 units sold) we would have heard about it by now. It would take HUGE sales to put a dent in that burn rate, and Im just not seeing it.
Look at the charts on all of these Book Value Bargains. I thought ROSG chart was bad until I looked at PARD. From $300 per share in late 2009 to 24 cents right now.